A Phase 2 interventional study of Quercetin (dietary supplement) and Placebo in Microvascular Dysfunction, Microvasculature and Cardiovascular Diseases, sponsored by Medical College of Wisconsin. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-04-29.
Sponsored by Medical College of Wisconsin · Phase 2, Interventional, and Basic science
The goal of this study is to learn how a supplement Quercetin can affect microvascular function.
Participants will:
Researchers will compare blood vessel function of those who take estrogen supplements to those who do not.
4,905 studies on the registry are indexed under Cardiovascular Diseases; 919 are open to participants now.
This study's planned enrollment of 40 is below the median of 100 across 2,738 interventional studies indexed under Cardiovascular Diseases.
Browse Cardiovascular Diseases studies →Medical College of Wisconsin is the lead sponsor of 540 studies on the registry; 119 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 56 (79%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Quercetin is a non-FDA approved, over-the-counter supplement that has been shown to improve oxidative capacity in blood vessels.
Dietary Supplement: Quercetin (dietary supplement)
A placebo will be administered for 30 days followed by assessment of the subject's microvascular function.
Drug: Placebo
Quercetin will be provided to take one Quercetin per day for 30 days to look for differences in microvascular function.
Subjects randomized to receive placebo will be administered a standard placebo sugar pill.
Change in blood vessel dilation
Peripheral microvascular dilation in response to acetylcholine, L-NAME, and sodium nitroprusside infusions will be measured using laser Doppler flowmetry with microdialysis.
Time frame: 2 hours
Change in Perfused Vessel Density
Total vessel density (TVD) will be calculated using the DeBacker Score manual analysis on all images that have a minimum microcirculation image quality score (MIQS) of 10. Perfused vessel density (PVD) will be calculated by multiplying total vessel density (TVD) x proportion of perfused vessels (PPV%).
Time frame: 0.5 hours
Plan to share: No
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medical College of Wisconsin